Both type 1 and type 2 diabetes can be treated and managed with healthy eating, physical activity, and taking medications such as insulin to control blood glucose levels. Yale is also conducting research to develop new treatments as well as prevent diabetes in those at risk.
Why Research Matters
In 1979 Dr. Robert Sherwin and Dr. William Tamborlane developed the insulin pump to treat type 1 diabetes. Today it’s used by more than 350,000 patients. Without volunteers like the children and their families who were willing to participate in clinical research, this groundbreaking discovery would not have been possible.
Tips for Controlling Diabetes
When you take care of your diabetes, you’ll feel better. You’ll reduce your risk for problems with your kidneys, eyes, nerves, feet and legs, and teeth. You’ll also lower your risk for a heart attack or a stroke. Your doctor may prescribe medication, but you can also take care of your diabetes by being physically active and following a healthy meal plan.
Research to Treat and Prevent Type 1 Diabetes
When Hannah Rosenfield was diagnosed with Type 1 diabetes at age 10, her mother Amy immediately looked beyond the standard treatment for something that might benefit her daughter long term.
Understanding the Root of Type 2 Diabetes
Dr. Gerald Shulman is working to uncover what happens in cells that leads to insulin resistance, which is at the core of type 2 diabetes. His research is pointing to new drug targets as well as exercise and dietary strategies that may lead to the reversal of insulin resistance and the prevention of type 2 diabetes.
Upcoming Diabetes Trial
A study comparing the effectiveness of three different classes of medications in patients already taking Metformin for Type 2 diabetes. Please check back in November for details.
Diabetes & Related Research Trials
- Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial ReleasePrincipal Investigator: Iris Isufi
- Hodgkin's Lymphoma, Non-Hodgkin's LymphomaLong-Term Follow-Up Study of Clinical Study Subjects Treated with An Autologous T Cell Product Expressing An Antibody-Coupled T-Cell Receptor (ACTR)Principal Investigator: Iris Isufi
- Melanoma, skinAn Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (Il-2v) Targeting Fibroblast Activation Protein-Α (Fap), In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic MelanomaPrincipal Investigator: Mario Sznol
- Child Development & AutismPET Imaging Study for Young Adults with ASDPrincipal Investigator: David Matuskey